Background: The emergence of infectious diseases and its resistance to approved drugs is a global threat to human health. The incidence of infectious diseases is increasing day by day and expected to rise exponentially in next 2 decades. Thus, there is a need for new treatment modalities for the treatment of microbial infections.
Objective: Thus, in the current investigation, we have explored the existing drugs [metformin (Anti-diabetic), propranolol (Anti-hypertensive), and amitriptyline (antidepressant)] for treatment of infectious diseases.
Results: An in-silico result of current investigation has shown the good interaction of metformin, propranolol, and amitriptyline towards various targets (Beta-lactamase, Penicillin-binding proteins, Staphylokinase protein, Oxidoreductase protein, etc.) of gram positive and gram negative bacteria as that of internal ligand. Further, in-vitro results have shown that the antibacterial activity of metformin, propranolol, and amitriptyline against Bacillus pumilus, Pseudomonas aeruginosa and Staphylococcus aureus.
Conclusion: The parameters such as Microtiter assay: percentage growth retardation and bacterial growth kinetics, Minimum inhibitory concentration (MIC), Post-antibiotic assay and Biofilm formation have indicated the antibacterial potential of metformin, propranolol, and amitriptyline. However, before starting a clinical trial, complete safety and efficacy profile of drugs in the treatment of infectious diseases should be investigated.
Keywords: Infectious diseases, Drug repurposition, In silico, In vitro studies
Mechanisms and Treatments of Oxidative Stress in Atrial Fibrillation
Current Pharmaceutical Design Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation
Current Pharmaceutical Design Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis
Current Vascular Pharmacology MMP-9, a Potential Target for Cerebral Ischemic Treatment
Current Neuropharmacology Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry Angiotensin 1-7 Promotes Cardiac Angiogenesis Following Infarction
Current Vascular Pharmacology 18F-fluoro-deoxy-D-glucose PET/CT in Establishing the Relationship Between the Metabolic Activity of Aorta and Iliac Artery Aneurysms in Cancer Patients
Current Medical Imaging Mitochondria: the Headquarters in Ischemia-Induced Neuronal Death
Central Nervous System Agents in Medicinal Chemistry Obstructive Sleep Apnea as an Independent Stroke Risk Factor: Possible Mechanisms
Current Molecular Medicine Special Issue on Programmed Cell Death in Stroke
Current Neuropharmacology Substituted Benzimidazole Derivatives as Angiotensin II -AT1 Receptor Antagonist: A Review
Mini-Reviews in Medicinal Chemistry Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Effects of Vitamin E and C on Placental Oxidative Stress: An In Vitro Evidence for the Potential Therapeutic or Prophylactic Treatment of Preeclampsia
Medicinal Chemistry Prospects for Caspase Inhibitors
Mini-Reviews in Medicinal Chemistry Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Current Molecular Medicine Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews